Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Abstract
All antiandrogen studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchAntiandrogensAntiandrogens (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Paxlovid Meta
Famotidine Meta Quercetin Meta
Favipiravir Meta Remdesivir Meta
Fluvoxamine Meta Thermotherapy Meta
Hydroxychlor.. Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Protective trend of anti-androgen therapy during the COVID-19 pandemic: A meta-analysis

Meng et al., Journal of Infection, doi:10.1016/j.jinf.2022.03.020
Mar 2022  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
7th treatment shown to reduce risk in September 2020
 
*, now with p = 0.000000056 from 49 studies.
No treatment is 100% effective. Protocols combine treatments. * >10% efficacy, ≥3 studies.
4,400+ studies for 79 treatments. c19early.org
Meta analysis of 15 antiandrogen studies showing a protective trend although there has been conflicting results to date.
2 meta analyses show significant improvements with antiandrogens for mortality1,2, hospitalization2, recovery2, and progression1.
Currently there are 49 antiandrogens for COVID-19 studies, showing 37% lower mortality [21‑50%], 47% lower ventilation [23‑64%], 36% lower ICU admission [5‑57%], 32% lower hospitalization [11‑48%], and 8% fewer cases [1‑14%].
Meng et al., 31 Mar 2022, peer-reviewed, 11 authors.
This PaperAntiandrogensAll
Protective trend of anti-androgen therapy during the COVID-19 pandemic: A meta-analysis
Jialin Meng, Qintao Ge, Jiawei Li, Xiaofan Lu, Yonghao Chen, Haitao Wang, Meng Zhang, Juan Du, Li Zhang, Zongyao Hao, Chaozhao Liang
Journal of Infection, doi:10.1016/j.jinf.2022.03.020
Protective trend of anti-androgen therapy during the COVID-19 pandemic: A meta-analysis Dear editor, Androgen receptor (AR) is an important transcription factor; thus, androgen and AR-associated pathways play pivotal roles in the progression of several diseases, including prostate cancer (PCa), benign prostatic hyperplasia (BPH), breast cancer, acne, and alopecia [ 1 , 2 ]. Anti-androgen therapy is widely used for the clinical treatment of prostatic diseases, including androgen deprivation therapy (ADT) via surgical castration, pharmacological castration,
Declaration of Competing Interest The authors have no conflicts of interest to declare. Supplementary materials Supplementary material associated with this article can be found, in the online version, at doi:10.1016/j.jinf.2022.03.020 .
References
Deng, Rasool, Russell, Natesan, Asangani, Targeting androgen regulation of TMPRSS2 and ACE2 as a therapeutic strategy to combat COVID-19, iScience
Leach, Mohr, Giotis, Cil, Isac et al., The antiandrogen enzalutamide downregulates TMPRSS2 and reduces cellular entry of SARS-CoV-2 in human lung cells, Nat Commun
Lyon, Li, Cullen, Milinovich, Kattan et al., 5alpha-reductase inhibitors are associated with reduced risk of SARS-CoV-2 infection: a matchedpair, registry-based analysis, J Urol
Marks, Prasad, Souza, Burns, Senna, Topical antiandrogen therapies for androgenetic alopecia and acne vulgaris, Am J Clin Dermatol
Montopoli, Zumerle, Vettor, Rugge, Zorzi et al., Androgen-deprivation therapies for prostate cancer and risk of infection by SARS-CoV-2: a population-based study (N = 4532), Ann Oncol
Qiao, Wang, Mannan, Pitchiaya, Zhang et al., Targeting transcriptional regulation of SARS-CoV-2 entry factors ACE2 and TMPRSS2, Proc Natl Acad Sci
Shukla, Plaga, Shankar, Gupta, Androgen receptor-related diseases: what do we know?, Andrology
Welen, Rosendal, Gisslen, Lenman, Freyhult et al., A phase 2 trial of the effect of antiandrogen therapy on COVID-19 Outcome: No evidence of benefit, supported by epidemiology and in vitro data, Eur Urol
{ 'indexed': {'date-parts': [[2022, 4, 4]], 'date-time': '2022-04-04T13:35:16Z', 'timestamp': 1649079316065}, 'reference-count': 8, 'publisher': 'Elsevier BV', 'license': [ { 'start': { 'date-parts': [[2022, 3, 1]], 'date-time': '2022-03-01T00:00:00Z', 'timestamp': 1646092800000}, 'content-version': 'tdm', 'delay-in-days': 0, 'URL': 'https://www.elsevier.com/tdm/userlicense/1.0/'}], 'funder': [ { 'DOI': '10.13039/501100001809', 'name': 'National Natural Science Foundation of China', 'doi-asserted-by': 'publisher'}], 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'short-container-title': ['Journal of Infection'], 'published-print': {'date-parts': [[2022, 3]]}, 'DOI': '10.1016/j.jinf.2022.03.020', 'type': 'journal-article', 'created': {'date-parts': [[2022, 3, 24]], 'date-time': '2022-03-24T23:24:56Z', 'timestamp': 1648164296000}, 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': ['Protective trend of anti-androgen therapy during the COVID-19 pandemic: A meta-analysis'], 'prefix': '10.1016', 'author': [ { 'ORCID': 'http://orcid.org/0000-0002-4622-833X', 'authenticated-orcid': False, 'given': 'Jialin', 'family': 'Meng', 'sequence': 'first', 'affiliation': []}, {'given': 'Qintao', 'family': 'Ge', 'sequence': 'additional', 'affiliation': []}, {'given': 'Jiawei', 'family': 'Li', 'sequence': 'additional', 'affiliation': []}, {'given': 'Xiaofan', 'family': 'Lu', 'sequence': 'additional', 'affiliation': []}, {'given': 'Yonghao', 'family': 'Chen', 'sequence': 'additional', 'affiliation': []}, {'given': 'Haitao', 'family': 'Wang', 'sequence': 'additional', 'affiliation': []}, {'given': 'Meng', 'family': 'Zhang', 'sequence': 'additional', 'affiliation': []}, {'given': 'Juan', 'family': 'Du', 'sequence': 'additional', 'affiliation': []}, {'given': 'Li', 'family': 'Zhang', 'sequence': 'additional', 'affiliation': []}, {'given': 'Zongyao', 'family': 'Hao', 'sequence': 'additional', 'affiliation': []}, {'given': 'Chaozhao', 'family': 'Liang', 'sequence': 'additional', 'affiliation': []}], 'member': '78', 'reference': [ { 'issue': '3', 'key': '10.1016/j.jinf.2022.03.020_bib0001', 'doi-asserted-by': 'crossref', 'first-page': '366', 'DOI': '10.1111/andr.12167', 'article-title': 'Androgen receptor-related diseases: what do we know?', 'volume': '4', 'author': 'Shukla', 'year': '2016', 'journal-title': 'Andrology'}, { 'issue': '2', 'key': '10.1016/j.jinf.2022.03.020_bib0002', 'doi-asserted-by': 'crossref', 'first-page': '245', 'DOI': '10.1007/s40257-019-00493-z', 'article-title': 'Topical antiandrogen therapies for androgenetic alopecia and acne ' 'vulgaris', 'volume': '21', 'author': 'Marks', 'year': '2020', 'journal-title': 'Am J Clin Dermatol'}, { 'issue': '8', 'key': '10.1016/j.jinf.2022.03.020_bib0003', 'doi-asserted-by': 'crossref', 'first-page': '1040', 'DOI': '10.1016/j.annonc.2020.04.479', 'article-title': 'Androgen-deprivation therapies for prostate cancer and risk of ' 'infection by SARS-CoV-2: a population-based study (N\xa0=\xa04532)', 'volume': '31', 'author': 'Montopoli', 'year': '2020', 'journal-title': 'Ann Oncol'}, { 'issue': '1', 'key': '10.1016/j.jinf.2022.03.020_bib0004', 'doi-asserted-by': 'crossref', 'first-page': '183', 'DOI': '10.1097/JU.0000000000002180', 'article-title': '5alpha-reductase inhibitors are associated with reduced risk of ' 'SARS-CoV-2 infection: a matched-pair, registry-based analysis', 'volume': '207', 'author': 'Lyon', 'year': '2022', 'journal-title': 'J Urol'}, { 'key': '10.1016/j.jinf.2022.03.020_bib0005', 'article-title': 'Targeting transcriptional regulation of SARS-CoV-2 entry factors ACE2 ' 'and TMPRSS2', 'author': 'Qiao', 'year': '2020', 'journal-title': 'Proc Natl Acad Sci U S A.'}, { 'issue': '1', 'key': '10.1016/j.jinf.2022.03.020_bib0006', 'doi-asserted-by': 'crossref', 'first-page': '4068', 'DOI': '10.1038/s41467-021-24342-y', 'article-title': 'The antiandrogen enzalutamide downregulates TMPRSS2 and reduces ' 'cellular entry of SARS-CoV-2 in human lung cells', 'volume': '12', 'author': 'Leach', 'year': '2021', 'journal-title': 'Nat Commun'}, { 'issue': '3', 'key': '10.1016/j.jinf.2022.03.020_bib0007', 'doi-asserted-by': 'crossref', 'DOI': '10.1016/j.isci.2021.102254', 'article-title': 'Targeting androgen regulation of TMPRSS2 and ACE2 as a therapeutic ' 'strategy to combat COVID-19', 'volume': '24', 'author': 'Deng', 'year': '2021', 'journal-title': 'iScience'}, { 'issue': '3', 'key': '10.1016/j.jinf.2022.03.020_bib0008', 'doi-asserted-by': 'crossref', 'first-page': '285', 'DOI': '10.1016/j.eururo.2021.12.013', 'article-title': 'A phase 2 trial of the effect of antiandrogen therapy on COVID-19 ' 'Outcome: No evidence of benefit, supported by epidemiology and in vitro ' 'data', 'volume': '81', 'author': 'Welen', 'year': '2022', 'journal-title': 'Eur Urol'}], 'container-title': ['Journal of Infection'], 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://api.elsevier.com/content/article/PII:S016344532200175X?httpAccept=text/xml', 'content-type': 'text/xml', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://api.elsevier.com/content/article/PII:S016344532200175X?httpAccept=text/plain', 'content-type': 'text/plain', 'content-version': 'vor', 'intended-application': 'text-mining'}], 'deposited': { 'date-parts': [[2022, 4, 2]], 'date-time': '2022-04-02T20:08:38Z', 'timestamp': 1648930118000}, 'score': 1, 'resource': {'primary': {'URL': 'https://linkinghub.elsevier.com/retrieve/pii/S016344532200175X'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2022, 3]]}, 'references-count': 8, 'alternative-id': ['S016344532200175X'], 'URL': 'http://dx.doi.org/10.1016/j.jinf.2022.03.020', 'relation': {}, 'ISSN': ['0163-4453'], 'issn-type': [{'value': '0163-4453', 'type': 'print'}], 'subject': ['Infectious Diseases', 'Microbiology (medical)'], 'published': {'date-parts': [[2022, 3]]}}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit